Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Novel Nutraceutical Supplement** is an investigational oral multi-ingredient nutraceutical supplement studied in overweight and obesity-related metabolic dysfunction. In the cited randomized double-blind clinical trial and associated translational program, it refers specifically to the silymarin-containing formulation composed of fructooligosaccharides, galactooligosaccharides, yeast beta-glucans from *Saccharomyces cerevisiae*, zinc, magnesium, selenomethionine, tixosil, and *Silybum marianum* extract. It is intended to act through complementary nutritional, prebiotic, immunomodulatory, antioxidant, and hepatoprotective effects rather than a single defined pharmacologic target, with proposed effects on obesity-associated endocrine and metabolic parameters and biomarkers linked to nonalcoholic fatty liver disease. The program appears to have been developed in an academic-industry setting involving the University of Sao Paulo General Hospital and Efeom Nutrição, with capsule administration at 4 capsules daily for 180 days in the reported human study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novel Nutraceutical Supplement.